GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products. (Q39063954)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

title

GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

author name string

Paolo Sbraccia

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

publication date

31 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

Eating and Weight Disorders

4 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

page(s)

231-240

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40519-016-0352-y

4 April 2020

exact match

0 references

cites work

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Omental adipose tissue fibrosis and insulin resistance in severe obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Iron status in obesity: An independent association with metabolic parameters and effect of weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Morning meal more efficient for fat loss in a 3-month lifestyle intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Effects of whole body vibration plus diet on insulin-resistance in middle-aged obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Inflammation in cardiac injury, repair and regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Cardiac fibroblasts: at the heart of myocardial remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Direct effect of GLP-1 infusion on endogenous glucose production in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Identification of the amyloid-degrading enzyme neprilysin in mouse islets and potential role in islet amyloidogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Reactive oxygen species in the regulation of synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

The GSK3 hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Lyase activities of CpcS- and CpcT-like proteins from Nostoc PCC7120 and sequential reconstitution of binding sites of phycoerythrocyanin and phycocyanin beta-subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Intracellular targeting of truncated secretory peptides in the mammalian heart and brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Mitochondrial targeting sequence of the influenza A virus PB1-F2 protein and its function in mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Efficient mitochondrial targeting relies on co-operation of multiple protein signals in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

The role of the Wnt signaling pathway in incretin hormone production and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Neprilysin, obesity and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Pharmacology, physiology, and mechanisms of incretin hormone action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto-Kakizaki rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40519-016-0352-Y

Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C.

21 January 2018

1 reference

12 December 2020

Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice

1 reference

12 December 2020

Cell-permeable, mitochondrial-targeted, peptide antioxidants

1 reference

12 December 2020

Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels

1 reference

12 December 2020

The mitochondrial targeting function of randomly generated peptide sequences correlates with predicted helical amphiphilicity

1 reference

12 December 2020

Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.

1 reference

12 December 2020

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

1 reference

12 December 2020

Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats

1 reference

12 December 2020

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

1 reference

12 December 2020

The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart

1 reference

12 December 2020

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

1 reference

12 December 2020

Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice

1 reference

12 December 2020

The glucagon-like peptides

1 reference

12 December 2020

Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells

1 reference

12 December 2020

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice

1 reference

12 December 2020

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

1 reference

12 December 2020

Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men

1 reference

12 December 2020

GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop

1 reference

12 December 2020

Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1

1 reference

12 December 2020

10.1007/S40519-016-0352-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28040864%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference